对比Cortexyne（纳斯达克股票代码：CRTX）和Acumen Pharmaceuticals（纳斯达克股票代码：ABOS）

Cortexyme (NASDAQ:CRTX – Get Rating) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by company insiders. Comparatively, 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cortexyme and Acumen Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cortexyme and Acumen Pharmaceuticals, as reported by MarketBeat.com.

Cortexyme presently has a consensus target price of $15.00, suggesting a potential upside of 1,356.31%. Acumen Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 232.71%. Given Cortexyme's higher possible upside, research analysts plainly believe Cortexyme is more favorable than Acumen Pharmaceuticals.

Earnings & Valuation

This table compares Cortexyme and Acumen Pharmaceuticals' revenue, earnings per share and valuation.

Cortexyme has higher earnings, but lower revenue than Acumen Pharmaceuticals.

Volatility and Risk

Cortexyme has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of -1.56, suggesting that its stock price is 256% less volatile than the S&P 500.

Summary

Acumen Pharmaceuticals beats Cortexyme on 5 of the 9 factors compared between the two stocks.

About Cortexyme

(Get Rating)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Acumen Pharmaceuticals

(Get Rating)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.